CALAA 01

Drug Profile

CALAA 01

Alternative Names: CALAA-01

Latest Information Update: 31 Aug 2012

Price : $50

At a glance

  • Originator Calando Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action Ribonucleotide reductase inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 31 Aug 2012 Calando completes enrolment in its phase Ib trial for refractory Solid tumours in the US
  • 09 Aug 2011 Calando completes enrolment in its phase I trial for Solid tumours in the US
  • 08 Jun 2010 Adverse events data from a phase I trial in Solid tumours presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top